Acute myeloid leukemia and other myelopathic disorders following treatment with alkylating agents.
Several large cohorts of patients treated with alkylating agents served as a means to review the clinical and pathologic features of 55 cases of myelopathic disorders that resulted. The incidence was 1.8% overall and consisted of five patients (9.9%) who developed bone marrow hypoplasia or aplasia, 15 (27.2%) who developed a myelodysplastic syndrome, and 35 cases of acute myeloid leukemia (62.9%). The median time to recognition of MPD was 14 months, following cessation of chemotherapy. The distribution of the treatment-related MDS cases was different than "de novo" MDS with a high percentage of RAEB-T, and with the treatment related AMLs, there were a higher percentage of patients with FAB M6 (erythroleukemia), and no cases of FAB M3 (hypergranular promyelocytic). The median survival of all patients was very brief.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000477:Alkylating Agents / Q000009:adverse effects*; D000741:Anemia, Aplastic / Q000139:chemically induced* / Q000235:genetics; D002648:Child; D002675:Child, Preschool; D002699:Chlorambucil / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007223:Infant; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000235:genetics / Q000473:pathology; D008297:Male; D008558:Melphalan / Q000009:adverse effects; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000139:chemically induced* / Q000235:genetics / Q000473:pathology; D010051:Ovarian Neoplasms / Q000150:complications / Q000188:drug therapy
D000477:Alkylating Agents; D002699:Chlorambucil; D003520:Cyclophosphamide; D008558:Melphalan